[1] Onda T, Tanaka YO, Kitai S, et al. Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602. Jpn J Clin Oncol. 2021;51(2):205-212.

[2] Fernandes, Maria Clara et al. “CT of Ovarian Cancer for Primary Treatment Planning: What the Surgeon Needs to Know-Radiology In Training.” Radiology vol. 304,3 (2022): 516-526.

[3] Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2018;143(Suppl 2):59–78.

[4] Querleu D, Planchamp F, Chiva L, et al. European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. Int J Gynecol Cancer 2017;27(7):1534–1542.

[5] Bryant A, Hiu S, Kunonga PT, et al. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. Cochrane Database Syst Rev. 2022;(9):CD015048.

[6] Pannu HK, Oliphant M. The subperitoneal space and peritoneal cavity: basic concepts. Abdom Imaging. 2015;40(7):2710-2722.

[7] Franconeri A, Boos J, Fang J, et al. Adnexal mass staging CT with a disease-specific structured report compared to simple structured report. Eur Radiol. 2019;29(9):4851-4860

Fig. 1 © Mutch, D.G., & Prat, J. (2014). 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecologic oncology, 133 3, 401-4 .

Fig. 2 - 4 © Dr. Adela Maskova

Fig. 5 - 14 © Department of Radiology nad Nuclear Medicine, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic